Featured Press Releases

Pyros Pharma announces VIGPODER™ (vigabatrin)

Pyros Pharma announces VIGPODER™ (vigabatrin)

FDA approves Apellis

FDA approves Apellis' EMPAVELI® (pegcetacoplan) as the first treatment for patients aged 12 and older with C3G and primary IC-MPGN

  • 30 Jul 2025

Apellis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has...

To Target the Multi-Billion Dollar Kidney Disease Market, Mezzion Expands Its Udenafil Pipeline to ADPKD

To Target the Multi-Billion Dollar Kidney Disease Market, Mezzion Expands Its Udenafil Pipeline to ADPKD

Cosette Pharmaceuticals names Vincent Colicchio as Senior Vice President of Operations

Cosette Pharmaceuticals names Vincent Colicchio as Senior Vice President of Operations

Peer-reviewed validation of a 60-channel closed-loop neurostimulation brain implant is published by Nia Therapeutics

Peer-reviewed validation of a 60-channel closed-loop neurostimulation brain implant is published by Nia Therapeutics

Queue Secures $12.6 Million to Launch the World

Queue Secures $12.6 Million to Launch the World's First Fully Autonomous Robotic Pharmacy

Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

  • Karyopharm Therapeutics Inc.
  • 31 Aug 2026
Choose Health Launches Comprehensive At-Home Liver Function Test Featuring 20+ Biomarkers and Clinical Risk Scores

Choose Health Launches Comprehensive At-Home Liver Function Test Featuring 20+ Biomarkers and Clinical Risk Scores

  • Choose Health
  • 28 Aug 2026
Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

  • Abbott
  • 26 Aug 2026
U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

  • Jazz Pharmaceuticals plc
  • 25 Aug 2026
European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

  • Acadia Pharmaceuticals Inc.
  • 24 Aug 2026
Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

  • Upsher-Smith Laboratories, LLC
  • 21 Aug 2026

Most Popular
September   2026
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.